Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuraxis, Inc. Common Stock (NY:NRXS)

7.700 -0.040 (-0.52%)
Delayed Quote Updated: 12:04 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neuraxis, Inc. Common Stock

< Previous 1 2 Next >
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
From iAccess Alpha
Via ACCESS Newswire
News headline image
NeurAxis (NRXS) Q2 2026 Earnings Call Transcript ↗
Revenue surged 116% as insurance coverage expanded and device pricing climbed. 
Via The Motley Fool
Topics Earnings
NeurAxis (NRXS) Q1 2026 Revenue and EPS Beat Drive Record Revenue and Strong Pre-Market Gains ↗
Via Chartmill
NeurAxis Inc (NYSEARCA:NRXS) Shows Strong Technical and Fundamental Momentum ↗
Via Chartmill
NeurAxis Inc (NYSEARCA:NRXS) Reports Q4 Revenue Beat Amid Mixed Market Reaction ↗
Via Chartmill
Neuraxis Inc (NRXS) Shows High Growth Momentum and Strong Technical Trend ↗
Via Chartmill
News headline image
Which stocks are gapping on Friday? ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Neuraxis Earnings Preview ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Earnings Outlook For Neuraxis ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
NRXS Stock Earnings: Neuraxis Reported Results for Q2 2024 ↗
Neuraxis just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Top movers in Tuesday's after hours session ↗
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Nasdaq Falls 100 Points; Home Depot Sales Top Views ↗
 
Via Benzinga
News headline image
NRXS Stock Earnings: Neuraxis Reported Results for Q1 2024 ↗
Neuraxis just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
NRXS Stock Earnings: Neuraxis Misses Revenue for Q4 2023 ↗
NRXS stock results show that Neuraxis missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Earnings Scheduled For March 20, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 9, 2024 ↗
Companies Reporting Before The Bell • Tilray Brands (NASDAQ:TLRY) is projected to report quarterly loss at $0.05 per share on revenue of $198.62 million. 
Via Benzinga
With Only 1.21 Million In The Trading Float, NeurAxis Stock Volatility Exposes An Opportunity, Not A Deterrent ($NRXS)
Via AB Newswire
News headline image
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock. 
Via Benzinga
News headline image
EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome ↗
NeurAxis Inc (NYSE: NRXS) announced the publication of a Prospective study evaluating the efficacy of IB-Stim in children featured in the September 2023 Frontiers in Pain Research. 
Via Benzinga
CEO Spotlight: NeurAxis CEO Explains His Better Way Of Treating Pediatric IBS And FAP ($NRXS)
Via AB Newswire
News headline image
NeurAxis Looks To Revolutionize The Treatment Of Adolescent Stomach Issues ↗
NeurAxis, Inc. (NYSEAMERICAN: NRXS) looks to revolutionize how pediatric irritable bowel syndrome (IBS) and functional abdominal pain (FAP) are treated.   
Via Benzinga
News headline image
EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids ↗
NeurAxis Inc (NYSE: NRXS) highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS), a... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.